### What this 6‑K is Avricore Health Inc. filed a Form 6‑K for December 2025 that primarily **furnishes Canadian interim filings**: CEO/CFO certifications plus **interim financial statements and interim MD&A for the period ended September 30, 2025**. ["Interim financial statements report for September 30, 2025"](0001493152-26-001689|0) ["Interim MD&A for September 30, 2025"](0001493152-26-001689|0) --- ## Really bad news (key negatives) - **Revenue collapse after Shoppers Drug Mart (SDM) ended.** Revenue fell **85% Y/Y to CAD $500,433** for the nine months ended Sep 30, 2025 and **97% Y/Y to CAD $37,680** for the three months ended Sep 30, 2025, which the company attributes to the **conclusion of the relationship with Shoppers Drug Mart**. ["revenue decreased by 85%"](0001493152-26-001689|4) ["revenue decreased by 97%"](0001493152-26-001689|4) ["due to the conclusion of the relationship with Shoppers Drug Mart"](0001493152-26-001689|4) - **Losses and cash burn.** Comprehensive loss was **CAD $916,042** for the nine months ended Sep 30, 2025 (vs income in 2024), and cash decreased by about **CAD $600k** over the nine-month period. ["comprehensive loss of $916,042"](0001493152-26-001689|4) ["Increase in cash and cash equivalents (600,111)"](0001493152-26-001689|3) - **Going concern language / material uncertainty.** The interim financial statements say there is a **“material uncertainty which may cast significant doubt”** on the company’s ability to continue as a going concern (dependent on revenues and/or financing). ["material uncertainty"](0001493152-26-001689|3) ["significant doubt"](0001493152-26-001689|3) - **Customer concentration risk remains (even though SDM is gone).** Notes indicate SDM was the major customer; the agreement expired March 31, 2025, and the company warns the loss of that major customer will significantly impact future revenue unless new sources are secured. ["agreement with the major customer expired on March 31, 2025"](0001493152-26-001689|3) ["will significantly impact the Company’s future revenue"](0001493152-26-001689|3) --- ## Really good news (key positives) - **UK traction + new pilot program.** The MD&A says **38 HealthTab systems were operating in the UK** as of Dec 1, 2025, and highlights a **new pilot** with **Barts Health NHS Trust** (with UCL Partners and the British Heart Foundation) to deliver **inclisiran cholesterol-lowering injections through community pharmacies**. ["38 HealthTabTM systems were operating in the UK"](0001493152-26-001689|4) ["new pilot launched by Barts Health NHS Trust"](0001493152-26-001689|4) ["deliver inclisiran"](0001493152-26-001689|4) - **Lower near-term capex needs via device redeployment.** Management states that with SDM operations concluded, devices can be redeployed, and management estimates **no investment in new devices for the next 12–18 months** (and expects resources to fund working capital over a similar window). ["will not require investment in new devices for the next 12 to 18 months"](0001493152-26-001689|4) ["sufficient to finance working capital for the next 12 to 18 months"](0001493152-26-001689|4) - **Liabilities appear low at Sep 30, 2025 (balance sheet snapshot).** Current liabilities (accounts payable/accrued) were **CAD $35,885** at Sep 30, 2025 versus **CAD $330,817** at Dec 31, 2024. ["Accounts payable and accrued liabilities 35,885"](0001493152-26-001689|3) ["330,817"](0001493152-26-001689|3) --- ## Bottom line This filing is mostly a **quarterly interim package** rather than a single discrete “event” announcement. ["Interim financial statements report"](0001493152-26-001689|0) The **headline negative** is the post‑SDM revenue cliff plus explicit going-concern uncertainty. ["revenue decreased by 85%"](0001493152-26-001689|4) ["material uncertainty"](0001493152-26-001689|3) The **headline positive** is evidence of a pivot to UK deployment and pilots, plus a stated plan to stretch cash by redeploying devices instead of buying new ones. ["38 HealthTabTM systems were operating in the UK"](0001493152-26-001689|4) ["will not require investment in new devices"](0001493152-26-001689|4)

### What this 6‑K is Avricore Health Inc. filed a Form 6‑K for December 2025 that primarily **furnishes Canadian interim filings**: CEO/CFO certifications plus **interim financial statements and interim MD&A for the period ended September 30, 2025**. ["Interim financial statements report for September 30, 2025"](0001493152-26-001689|0) ["Interim MD&A for September 30, 2025"](0001493152-26-001689|0) --- ## Really bad news (key negatives) - **Revenue collapse after Shoppers Drug Mart (SDM) ended.** Revenue fell **85% Y/Y to CAD $500,433** for the nine months ended Sep 30, 2025 and **97% Y/Y to CAD $37,680** for the three months ended Sep 30, 2025, which the company attributes to the **conclusion of the relationship with Shoppers Drug Mart**. ["revenue decreased by 85%"](0001493152-26-001689|4) ["revenue decreased by 97%"](0001493152-26-001689|4) ["due to the conclusion of the relationship with Shoppers Drug Mart"](0001493152-26-001689|4) - **Losses and cash burn.** Comprehensive loss was **CAD $916,042** for the nine months ended Sep 30, 2025 (vs income in 2024), and cash decreased by about **CAD $600k** over the nine-month period. ["comprehensive loss of $916,042"](0001493152-26-001689|4) ["Increase in cash and cash equivalents (600,111)"](0001493152-26-001689|3) - **Going concern language / material uncertainty.** The interim financial statements say there is a **“material uncertainty which may cast significant doubt”** on the company’s ability to continue as a going concern (dependent on revenues and/or financing). ["material uncertainty"](0001493152-26-001689|3) ["significant doubt"](0001493152-26-001689|3) - **Customer concentration risk remains (even though SDM is gone).** Notes indicate SDM was the major customer; the agreement expired March 31, 2025, and the company warns the loss of that major customer will significantly impact future revenue unless new sources are secured. ["agreement with the major customer expired on March 31, 2025"](0001493152-26-001689|3) ["will significantly impact the Company’s future revenue"](0001493152-26-001689|3) --- ## Really good news (key positives) - **UK traction + new pilot program.** The MD&A says **38 HealthTab systems were operating in the UK** as of Dec 1, 2025, and highlights a **new pilot** with **Barts Health NHS Trust** (with UCL Partners and the British Heart Foundation) to deliver **inclisiran cholesterol-lowering injections through community pharmacies**. ["38 HealthTabTM systems were operating in the UK"](0001493152-26-001689|4) ["new pilot launched by Barts Health NHS Trust"](0001493152-26-001689|4) ["deliver inclisiran"](0001493152-26-001689|4) - **Lower near-term capex needs via device redeployment.** Management states that with SDM operations concluded, devices can be redeployed, and management estimates **no investment in new devices for the next 12–18 months** (and expects resources to fund working capital over a similar window). ["will not require investment in new devices for the next 12 to 18 months"](0001493152-26-001689|4) ["sufficient to finance working capital for the next 12 to 18 months"](0001493152-26-001689|4) - **Liabilities appear low at Sep 30, 2025 (balance sheet snapshot).** Current liabilities (accounts payable/accrued) were **CAD $35,885** at Sep 30, 2025 versus **CAD $330,817** at Dec 31, 2024. ["Accounts payable and accrued liabilities 35,885"](0001493152-26-001689|3) ["330,817"](0001493152-26-001689|3) --- ## Bottom line This filing is mostly a **quarterly interim package** rather than a single discrete “event” announcement. ["Interim financial statements report"](0001493152-26-001689|0) The **headline negative** is the post‑SDM revenue cliff plus explicit going-concern uncertainty. ["revenue decreased by 85%"](0001493152-26-001689|4) ["material uncertainty"](0001493152-26-001689|3) The **headline positive** is evidence of a pivot to UK deployment and pilots, plus a stated plan to stretch cash by redeploying devices instead of buying new ones. ["38 HealthTabTM systems were operating in the UK"](0001493152-26-001689|4) ["will not require investment in new devices"](0001493152-26-001689|4)